ID   DDR2_HUMAN              Reviewed;         855 AA.
AC   Q16832; Q7Z730;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   12-OCT-2022, entry version 211.
DE   RecName: Full=Discoidin domain-containing receptor 2;
DE            Short=Discoidin domain receptor 2;
DE            EC=2.7.10.1;
DE   AltName: Full=CD167 antigen-like family member B;
DE   AltName: Full=Discoidin domain-containing receptor tyrosine kinase 2;
DE   AltName: Full=Neurotrophic tyrosine kinase, receptor-related 3;
DE   AltName: Full=Receptor protein-tyrosine kinase TKT;
DE   AltName: Full=Tyrosine-protein kinase TYRO10;
DE   AltName: CD_antigen=CD167b;
DE   Flags: Precursor;
GN   Name=DDR2; Synonyms=NTRKR3, TKT, TYRO10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Heart, and Thymus;
RX   PubMed=8247548;
RA   Karn T., Holtrich U., Braeuninger A., Boehme B., Wolf G.,
RA   Ruebsamen-Waigmann H., Strebhardt K.;
RT   "Structure, expression and chromosomal mapping of TKT from man and mouse: a
RT   new subclass of receptor tyrosine kinases with a factor VIII-like domain.";
RL   Oncogene 8:3433-3440(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Hair follicle dermal papilla, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION AS COLLAGEN RECEPTOR AND IN UP-REGULATION OF MMP1,
RP   PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9659899; DOI=10.1016/s1097-2765(00)80003-9;
RA   Vogel W., Gish G.D., Alves F., Pawson T.;
RT   "The discoidin domain receptor tyrosine kinases are activated by
RT   collagen.";
RL   Mol. Cell 1:13-23(1997).
RN   [7]
RP   FUNCTION IN REGULATION OF MMP1 AND MMP2, PHOSPHORYLATION AT TYR-736;
RP   TYR-740 AND TYR-741, CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION
RP   WITH SHC1, AND MUTAGENESIS OF LYS-608; TYR-736; TYR-740 AND TYR-741.
RX   PubMed=16186108; DOI=10.1074/jbc.m506921200;
RA   Yang K., Kim J.H., Kim H.J., Park I.S., Kim I.Y., Yang B.S.;
RT   "Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src
RT   stimulates intramolecular autophosphorylation and Shc signaling complex
RT   formation.";
RL   J. Biol. Chem. 280:39058-39066(2005).
RN   [8]
RP   FUNCTION AS COLLAGEN RECEPTOR, AND PHOSPHORYLATION.
RX   PubMed=16186104; DOI=10.1074/jbc.m508226200;
RA   Wall S.J., Werner E., Werb Z., DeClerck Y.A.;
RT   "Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by
RT   fibrillar collagen.";
RL   J. Biol. Chem. 280:40187-40194(2005).
RN   [9]
RP   FUNCTION IN UP-REGULATION OF MMP13, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=17665456; DOI=10.1002/art.22761;
RA   Xu L., Peng H., Glasson S., Lee P.L., Hu K., Ijiri K., Olsen B.R.,
RA   Goldring M.B., Li Y.;
RT   "Increased expression of the collagen receptor discoidin domain receptor 2
RT   in articular cartilage as a key event in the pathogenesis of
RT   osteoarthritis.";
RL   Arthritis Rheum. 56:2663-2673(2007).
RN   [10]
RP   FUNCTION AS COLLAGEN RECEPTOR, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND
RP   SUBUNIT.
RX   PubMed=18201965; DOI=10.1074/jbc.m709290200;
RA   Konitsiotis A.D., Raynal N., Bihan D., Hohenester E., Farndale R.W.,
RA   Leitinger B.;
RT   "Characterization of high affinity binding motifs for the discoidin domain
RT   receptor DDR2 in collagen.";
RL   J. Biol. Chem. 283:6861-6868(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION VIA ACTIVATION OF RUNX2, INDUCTION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=20564243; DOI=10.1002/jbmr.159;
RA   Lin K.L., Chou C.H., Hsieh S.C., Hwa S.Y., Lee M.T., Wang F.F.;
RT   "Transcriptional upregulation of DDR2 by ATF4 facilitates osteoblastic
RT   differentiation through p38 MAPK-mediated Runx2 activation.";
RL   J. Bone Miner. Res. 25:2489-2503(2010).
RN   [14]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION AND CHONDROCYTE MATURATION VIA
RP   ACTIVATION OF RUNX2.
RX   PubMed=20734453; DOI=10.1002/jbmr.225;
RA   Zhang Y., Su J., Yu J., Bu X., Ren T., Liu X., Yao L.;
RT   "An essential role of discoidin domain receptor 2 (DDR2) in osteoblast
RT   differentiation and chondrocyte maturation via modulation of Runx2
RT   activation.";
RL   J. Bone Miner. Res. 26:604-617(2011).
RN   [15]
RP   REVIEW.
RX   PubMed=16626936; DOI=10.1016/j.cellsig.2006.02.012;
RA   Vogel W.F., Abdulhussein R., Ford C.E.;
RT   "Sensing extracellular matrix: an update on discoidin domain receptor
RT   function.";
RL   Cell. Signal. 18:1108-1116(2006).
RN   [16]
RP   REVIEW.
RX   PubMed=21568710; DOI=10.1146/annurev-cellbio-092910-154013;
RA   Leitinger B.;
RT   "Transmembrane collagen receptors.";
RL   Annu. Rev. Cell Dev. Biol. 27:265-290(2011).
RN   [17]
RP   STRUCTURE BY NMR OF 22-186, INTERACTION WITH COLLAGEN, AND DISULFIDE BONDS.
RX   PubMed=17703188; DOI=10.1038/sj.emboj.7601833;
RA   Ichikawa O., Osawa M., Nishida N., Goshima N., Nomura N., Shimada I.;
RT   "Structural basis of the collagen-binding mode of discoidin domain receptor
RT   2.";
RL   EMBO J. 26:4168-4176(2007).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 26-190 IN COMPLEX WITH COLLAGEN
RP   PEPTIDE, DISULFIDE BONDS, MUTAGENESIS OF TRP-52, FUNCTION IN COLLAGEN
RP   BINDING, CATALYTIC ACTIVITY, AND PHOSPHORYLATION.
RX   PubMed=20004161; DOI=10.1016/j.str.2009.10.012;
RA   Carafoli F., Bihan D., Stathopoulos S., Konitsiotis A.D., Kvansakul M.,
RA   Farndale R.W., Leitinger B., Hohenester E.;
RT   "Crystallographic insight into collagen recognition by discoidin domain
RT   receptor 2.";
RL   Structure 17:1573-1581(2009).
RN   [19]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-105.
RX   PubMed=16140923; DOI=10.1158/0008-5472.can-05-1855;
RA   Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G.,
RA   Teague J., Butler A., Edkins S., Stevens C., Parker A., O'Meara S.,
RA   Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J.,
RA   Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K.,
RA   Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R.,
RA   Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A.,
RA   Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S.,
RA   Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M.,
RA   Leung S.Y., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B.T.,
RA   Yuen S.T., Lakhani S.R., Easton D.F., Weber B.L., Goldstraw P.,
RA   Nicholson A.G., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Somatic mutations of the protein kinase gene family in human lung
RT   cancer.";
RL   Cancer Res. 65:7591-7595(2005).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-105; ILE-441; CYS-478 AND PHE-543.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [21]
RP   VARIANTS SEMD-SL ILE-713; ARG-726 AND CYS-752.
RX   PubMed=19110212; DOI=10.1016/j.ajhg.2008.12.004;
RA   Bargal R., Cormier-Daire V., Ben-Neriah Z., Le Merrer M., Sosna J.,
RA   Melki J., Zangen D.H., Smithson S.F., Borochowitz Z., Belostotsky R.,
RA   Raas-Rothschild A.;
RT   "Mutations in DDR2 gene cause SMED with short limbs and abnormal
RT   calcifications.";
RL   Am. J. Hum. Genet. 84:80-84(2009).
RN   [22]
RP   VARIANT SEMD-SL LYS-113, CHARACTERIZATION OF VARIANTS SEMD-SL LYS-113;
RP   ILE-713; ARG-726 AND CYS-752, MUTAGENESIS OF TRP-52, GLYCOSYLATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20223752; DOI=10.1093/hmg/ddq103;
RA   Ali B.R., Xu H., Akawi N.A., John A., Karuvantevida N.S., Langer R.,
RA   Al-Gazali L., Leitinger B.;
RT   "Trafficking defects and loss of ligand binding are the underlying causes
RT   of all reported DDR2 missense mutations found in SMED-SL patients.";
RL   Hum. Mol. Genet. 19:2239-2250(2010).
RN   [23]
RP   VARIANT SEMD-SL TRP-124.
RX   PubMed=26463668; DOI=10.1002/ajmg.a.37426;
RA   Mansouri M., Kayserili H., Elalaoui S.C., Nishimura G., Iida A.,
RA   Lyahyai J., Miyake N., Matsumoto N., Sefiani A., Ikegawa S.;
RT   "Novel DDR2 mutation identified by whole exome sequencing in a Moroccan
RT   patient with spondylo-meta-epiphyseal dysplasia, short limb-abnormal
RT   calcification type.";
RL   Am. J. Med. Genet. A 170:460-465(2016).
RN   [24]
RP   VARIANTS WRCN PRO-610 AND CYS-740, CHARACTERIZATION OF VARIANTS WRCN
RP   PRO-610 AND CYS-740, FUNCTION, AND INVOLVEMENT IN WRCN.
RX   PubMed=30449416; DOI=10.1016/j.ajhg.2018.10.013;
RA   Xu L., Jensen H., Johnston J.J., Di Maria E., Kloth K., Cristea I.,
RA   Sapp J.C., Darling T.N., Huryn L.A., Tranebjaerg L., Cinotti E.,
RA   Kubisch C., Roedahl E., Bruland O., Biesecker L.G., Houge G., Bredrup C.;
RT   "Recurrent, activating variants in the receptor tyrosine kinase DDR2 cause
RT   Warburg-Cinotti syndrome.";
RL   Am. J. Hum. Genet. 103:976-983(2018).
CC   -!- FUNCTION: Tyrosine kinase involved in the regulation of tissues
CC       remodeling (PubMed:30449416). It functions as cell surface receptor for
CC       fibrillar collagen and regulates cell differentiation, remodeling of
CC       the extracellular matrix, cell migration and cell proliferation.
CC       Required for normal bone development. Regulates osteoblast
CC       differentiation and chondrocyte maturation via a signaling pathway that
CC       involves MAP kinases and leads to the activation of the transcription
CC       factor RUNX2. Regulates remodeling of the extracellular matrix by up-
CC       regulation of the collagenases MMP1, MMP2 and MMP13, and thereby
CC       facilitates cell migration and tumor cell invasion. Promotes fibroblast
CC       migration and proliferation, and thereby contributes to cutaneous wound
CC       healing. {ECO:0000269|PubMed:16186104, ECO:0000269|PubMed:16186108,
CC       ECO:0000269|PubMed:17665456, ECO:0000269|PubMed:18201965,
CC       ECO:0000269|PubMed:20004161, ECO:0000269|PubMed:20564243,
CC       ECO:0000269|PubMed:20734453, ECO:0000269|PubMed:30449416,
CC       ECO:0000269|PubMed:9659899}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:16186108, ECO:0000269|PubMed:20004161};
CC   -!- ACTIVITY REGULATION: Present in an inactive state in the absence of
CC       collagen binding and phosphorylation by SRC. Tyrosine phosphorylation
CC       enhances the affinity for ATP and the catalytic activity.
CC       {ECO:0000269|PubMed:16186108}.
CC   -!- SUBUNIT: Binds hydroxyproline-rich sequence motifs in fibrillar,
CC       glycosylated collagen, such as the GQOGVMGFO motif, where O stands for
CC       hydroxyproline. Interacts with SRC. Interacts (tyrosine phosphorylated)
CC       with SHC1. {ECO:0000269|PubMed:16186108, ECO:0000269|PubMed:17703188,
CC       ECO:0000269|PubMed:18201965, ECO:0000269|PubMed:20004161}.
CC   -!- INTERACTION:
CC       Q16832; Q16543: CDC37; NbExp=3; IntAct=EBI-1381484, EBI-295634;
CC       Q16832; P13942: COL11A2; NbExp=2; IntAct=EBI-1381484, EBI-2515504;
CC       Q16832; Q08345: DDR1; NbExp=2; IntAct=EBI-1381484, EBI-711879;
CC       Q16832; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1381484, EBI-352572;
CC       Q16832; Q16288: NTRK3; NbExp=2; IntAct=EBI-1381484, EBI-3936704;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18201965,
CC       ECO:0000269|PubMed:20223752, ECO:0000269|PubMed:9659899}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:18201965,
CC       ECO:0000269|PubMed:20223752, ECO:0000269|PubMed:9659899}.
CC   -!- TISSUE SPECIFICITY: Detected in osteocytes, osteoblastic cells in
CC       subchondral bone, bone lining cells, tibia and cartilage (at protein
CC       level). Detected at high levels in heart and lung, and at low levels in
CC       brain, placenta, liver, skeletal muscle, pancreas, and kidney.
CC       {ECO:0000269|PubMed:17665456, ECO:0000269|PubMed:20564243,
CC       ECO:0000269|PubMed:8247548}.
CC   -!- INDUCTION: Up-regulated during osteoblast differentiation (in vitro).
CC       Up-regulated in cartilage from osteoarthritis patients.
CC       {ECO:0000269|PubMed:17665456, ECO:0000269|PubMed:20564243}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20223752}.
CC   -!- PTM: Tyrosine phosphorylated in response to collagen binding.
CC       Phosphorylated by SRC; this is required for activation and subsequent
CC       autophosphorylation on additional tyrosine residues.
CC       {ECO:0000269|PubMed:16186104, ECO:0000269|PubMed:16186108,
CC       ECO:0000269|PubMed:18201965, ECO:0000269|PubMed:20004161,
CC       ECO:0000269|PubMed:9659899}.
CC   -!- DISEASE: Spondyloepimetaphyseal dysplasia, short limb-hand type (SEMD-
CC       SL) [MIM:271665]: A bone disease characterized by short-limbed
CC       dwarfism, a narrow chest with pectus excavatum, brachydactyly in the
CC       hands and feet, a characteristic craniofacial appearance and premature
CC       calcifications. The radiological findings are distinctive and comprise
CC       short long bones throughout the skeleton with striking epiphyses that
CC       are stippled, flattened and fragmented and flared, irregular
CC       metaphyses. Platyspondyly in the spine with wide intervertebral spaces
CC       is observed and some vertebral bodies are pear-shaped with central
CC       humps, anterior protrusions and posterior scalloping.
CC       {ECO:0000269|PubMed:19110212, ECO:0000269|PubMed:20223752,
CC       ECO:0000269|PubMed:26463668}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Warburg-Cinotti syndrome (WRCN) [MIM:618175]: An autosomal
CC       dominant disease characterized by progressive corneal
CC       neovascularization, keloid formation, chronic skin ulcers, wasting of
CC       subcutaneous tissue, flexion contractures of the fingers, and acro-
CC       osteolysis. {ECO:0000269|PubMed:30449416}. Note=The disease is caused
CC       by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X74764; CAA52777.1; -; mRNA.
DR   EMBL; AK314388; BAG37013.1; -; mRNA.
DR   EMBL; AK095975; BAG53183.1; -; mRNA.
DR   EMBL; AL445197; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471067; EAW90713.1; -; Genomic_DNA.
DR   EMBL; BC052998; AAH52998.1; -; mRNA.
DR   CCDS; CCDS1241.1; -.
DR   PIR; S42621; S42621.
DR   RefSeq; NP_001014796.1; NM_001014796.1.
DR   RefSeq; NP_006173.2; NM_006182.2.
DR   RefSeq; XP_006711407.1; XM_006711344.3.
DR   RefSeq; XP_011507888.1; XM_011509586.2.
DR   RefSeq; XP_011507889.1; XM_011509587.2.
DR   PDB; 2WUH; X-ray; 1.60 A; A=26-190.
DR   PDB; 2Z4F; NMR; -; A=26-186.
DR   PDB; 6FER; X-ray; 2.87 A; A/B/C/D/E/F/G/H/I/J/K/L=553-855.
DR   PDB; 7AZB; X-ray; 2.62 A; A=26-190.
DR   PDBsum; 2WUH; -.
DR   PDBsum; 2Z4F; -.
DR   PDBsum; 6FER; -.
DR   PDBsum; 7AZB; -.
DR   AlphaFoldDB; Q16832; -.
DR   BMRB; Q16832; -.
DR   SMR; Q16832; -.
DR   BioGRID; 110975; 24.
DR   DIP; DIP-39699N; -.
DR   IntAct; Q16832; 121.
DR   MINT; Q16832; -.
DR   STRING; 9606.ENSP00000356899; -.
DR   BindingDB; Q16832; -.
DR   ChEMBL; CHEMBL5122; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugCentral; Q16832; -.
DR   GuidetoPHARMACOLOGY; 1844; -.
DR   GlyGen; Q16832; 5 sites.
DR   iPTMnet; Q16832; -.
DR   PhosphoSitePlus; Q16832; -.
DR   SwissPalm; Q16832; -.
DR   BioMuta; DDR2; -.
DR   DMDM; 215273969; -.
DR   EPD; Q16832; -.
DR   jPOST; Q16832; -.
DR   MassIVE; Q16832; -.
DR   MaxQB; Q16832; -.
DR   PaxDb; Q16832; -.
DR   PeptideAtlas; Q16832; -.
DR   PRIDE; Q16832; -.
DR   ProteomicsDB; 61095; -.
DR   Antibodypedia; 4177; 471 antibodies from 35 providers.
DR   DNASU; 4921; -.
DR   Ensembl; ENST00000367921.8; ENSP00000356898.3; ENSG00000162733.19.
DR   Ensembl; ENST00000367922.7; ENSP00000356899.2; ENSG00000162733.19.
DR   Ensembl; ENST00000446985.6; ENSP00000400309.2; ENSG00000162733.19.
DR   GeneID; 4921; -.
DR   KEGG; hsa:4921; -.
DR   MANE-Select; ENST00000367921.8; ENSP00000356898.3; NM_006182.4; NP_006173.2.
DR   UCSC; uc001gcg.4; human.
DR   CTD; 4921; -.
DR   DisGeNET; 4921; -.
DR   GeneCards; DDR2; -.
DR   HGNC; HGNC:2731; DDR2.
DR   HPA; ENSG00000162733; Low tissue specificity.
DR   MalaCards; DDR2; -.
DR   MIM; 191311; gene.
DR   MIM; 271665; phenotype.
DR   MIM; 618175; phenotype.
DR   neXtProt; NX_Q16832; -.
DR   OpenTargets; ENSG00000162733; -.
DR   Orphanet; 93358; Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome.
DR   PharmGKB; PA27196; -.
DR   VEuPathDB; HostDB:ENSG00000162733; -.
DR   eggNOG; KOG1094; Eukaryota.
DR   GeneTree; ENSGT00940000154842; -.
DR   HOGENOM; CLU_008873_2_0_1; -.
DR   InParanoid; Q16832; -.
DR   OMA; FTFCREQ; -.
DR   OrthoDB; 227725at2759; -.
DR   PhylomeDB; Q16832; -.
DR   TreeFam; TF317840; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; Q16832; -.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   SignaLink; Q16832; -.
DR   SIGNOR; Q16832; -.
DR   BioGRID-ORCS; 4921; 9 hits in 1100 CRISPR screens.
DR   ChiTaRS; DDR2; human.
DR   EvolutionaryTrace; Q16832; -.
DR   GeneWiki; Discoidin_domain-containing_receptor_2; -.
DR   GenomeRNAi; 4921; -.
DR   Pharos; Q16832; Tchem.
DR   PRO; PR:Q16832; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q16832; protein.
DR   Bgee; ENSG00000162733; Expressed in cauda epididymis and 197 other tissues.
DR   ExpressionAtlas; Q16832; baseline and differential.
DR   Genevisible; Q16832; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0038062; F:protein tyrosine kinase collagen receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031214; P:biomineral tissue development; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:1904385; P:cellular response to angiotensin; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0035988; P:chondrocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:UniProtKB.
DR   GO; GO:0038063; P:collagen-activated tyrosine kinase receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0003416; P:endochondral bone growth; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:1901299; P:negative regulation of hydrogen peroxide-mediated programmed cell death; IEA:Ensembl.
DR   GO; GO:0033673; P:negative regulation of kinase activity; IEA:Ensembl.
DR   GO; GO:0060547; P:negative regulation of necrotic cell death; IEA:Ensembl.
DR   GO; GO:0001503; P:ossification; IEA:UniProtKB-KW.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0090091; P:positive regulation of extracellular matrix disassembly; ISS:UniProtKB.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; ISS:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; ISS:UniProtKB.
DR   GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:2000491; P:positive regulation of hepatic stellate cell activation; IEA:Ensembl.
DR   GO; GO:1904899; P:positive regulation of hepatic stellate cell proliferation; IEA:Ensembl.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:1901216; P:positive regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:UniProtKB.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0090303; P:positive regulation of wound healing; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0030500; P:regulation of bone mineralization; IMP:UniProtKB.
DR   GO; GO:0010715; P:regulation of extracellular matrix disassembly; TAS:UniProtKB.
DR   GO; GO:0034103; P:regulation of tissue remodeling; IMP:UniProtKB.
DR   GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd00057; FA58C; 1.
DR   InterPro; IPR034299; DDR1/DDR2.
DR   InterPro; IPR000421; FA58C.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF295; PTHR24416:SF295; 1.
DR   Pfam; PF00754; F5_F8_type_C; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00231; FA58C; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01285; FA58C_1; 1.
DR   PROSITE; PS01286; FA58C_2; 1.
DR   PROSITE; PS50022; FA58C_3; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Disease variant; Disulfide bond;
KW   Dwarfism; Glycoprotein; Kinase; Membrane; Nucleotide-binding; Osteogenesis;
KW   Phosphoprotein; Receptor; Reference proteome; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000255"
FT   CHAIN           22..855
FT                   /note="Discoidin domain-containing receptor 2"
FT                   /id="PRO_0000016746"
FT   TOPO_DOM        22..399
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        400..421
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        422..855
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          30..185
FT                   /note="F5/8 type C"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00081"
FT   DOMAIN          563..849
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          452..471
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        710
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         569..577
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         608
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         471
FT                   /note="Phosphotyrosine; by SRC and autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q62371"
FT   MOD_RES         736
FT                   /note="Phosphotyrosine; by SRC and autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16186108"
FT   MOD_RES         740
FT                   /note="Phosphotyrosine; by SRC and autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16186108"
FT   MOD_RES         741
FT                   /note="Phosphotyrosine; by SRC and autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16186108"
FT   CARBOHYD        121
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        213
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        261
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        280
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        372
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        30..185
FT   DISULFID        73..177
FT   VARIANT         105
FT                   /note="R -> S (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:16140923,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041498"
FT   VARIANT         113
FT                   /note="E -> K (in SEMD-SL; abolishes collagen binding;
FT                   dbSNP:rs397514747)"
FT                   /evidence="ECO:0000269|PubMed:20223752"
FT                   /id="VAR_065719"
FT   VARIANT         124
FT                   /note="R -> W (in SEMD-SL)"
FT                   /evidence="ECO:0000269|PubMed:26463668"
FT                   /id="VAR_075417"
FT   VARIANT         441
FT                   /note="M -> I (in dbSNP:rs34722354)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041499"
FT   VARIANT         478
FT                   /note="R -> C (in dbSNP:rs34869543)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041500"
FT   VARIANT         543
FT                   /note="V -> F (in dbSNP:rs55973200)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041501"
FT   VARIANT         610
FT                   /note="L -> P (in WRCN; increased autophosphorylation in
FT                   patient fibroblasts)"
FT                   /evidence="ECO:0000269|PubMed:30449416"
FT                   /id="VAR_081931"
FT   VARIANT         713
FT                   /note="T -> I (in SEMD-SL; causes retention in an
FT                   intracellular compartment and thereby abolishes signaling
FT                   in response collagen binding; dbSNP:rs121964865)"
FT                   /evidence="ECO:0000269|PubMed:19110212,
FT                   ECO:0000269|PubMed:20223752"
FT                   /id="VAR_063050"
FT   VARIANT         726
FT                   /note="I -> R (in SEMD-SL; causes retention in an
FT                   intracellular compartment and thereby abolishes signaling
FT                   in response collagen binding; dbSNP:rs121964864)"
FT                   /evidence="ECO:0000269|PubMed:19110212,
FT                   ECO:0000269|PubMed:20223752"
FT                   /id="VAR_063051"
FT   VARIANT         740
FT                   /note="Y -> C (in WRCN; increased autophosphorylation in
FT                   patient fibroblasts)"
FT                   /evidence="ECO:0000269|PubMed:30449416"
FT                   /id="VAR_081932"
FT   VARIANT         752
FT                   /note="R -> C (in SEMD-SL; causes retention in an
FT                   intracellular compartment and thereby abolishes signaling
FT                   in response collagen binding; dbSNP:rs121964863)"
FT                   /evidence="ECO:0000269|PubMed:19110212,
FT                   ECO:0000269|PubMed:20223752"
FT                   /id="VAR_063052"
FT   MUTAGEN         52
FT                   /note="W->A: Abolishes collagen binding."
FT                   /evidence="ECO:0000269|PubMed:20004161,
FT                   ECO:0000269|PubMed:20223752"
FT   MUTAGEN         608
FT                   /note="K->A: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:16186108"
FT   MUTAGEN         736
FT                   /note="Y->F: Reduces autophosphorylation. Abolishes
FT                   phosphorylation by SRC; when associated with F-740 and
FT                   F-741."
FT                   /evidence="ECO:0000269|PubMed:16186108"
FT   MUTAGEN         740
FT                   /note="Y->F: Promotes autophosphorylation. Abolishes
FT                   phosphorylation by SRC; when associated with F-736 and
FT                   F-741."
FT                   /evidence="ECO:0000269|PubMed:16186108"
FT   MUTAGEN         741
FT                   /note="Y->F: Reduces autophosphorylation. Abolishes
FT                   phosphorylation by SRC; when associated with F-736 and
FT                   F-740."
FT                   /evidence="ECO:0000269|PubMed:16186108"
FT   CONFLICT        642
FT                   /note="A -> S (in Ref. 1; CAA52777)"
FT                   /evidence="ECO:0000305"
FT   TURN            27..29
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   STRAND          33..35
FT                   /evidence="ECO:0007829|PDB:2Z4F"
FT   TURN            36..38
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   STRAND          39..41
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   HELIX           43..45
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   STRAND          46..49
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   HELIX           54..56
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   HELIX           58..60
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   STRAND          70..72
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   STRAND          87..103
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   HELIX           107..109
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   STRAND          116..128
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   STRAND          135..137
FT                   /evidence="ECO:0007829|PDB:7AZB"
FT   STRAND          140..142
FT                   /evidence="ECO:0007829|PDB:7AZB"
FT   STRAND          145..149
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   STRAND          151..169
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   STRAND          171..174
FT                   /evidence="ECO:0007829|PDB:7AZB"
FT   STRAND          178..186
FT                   /evidence="ECO:0007829|PDB:2WUH"
FT   HELIX           560..562
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          565..571
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          576..581
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          604..609
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           616..630
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          642..644
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          646..649
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          651..655
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           662..667
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           684..703
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           713..715
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          716..718
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           720..722
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          724..726
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           734..739
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          744..746
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   TURN            751..753
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           756..759
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           766..782
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   TURN            788..791
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           794..806
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   STRAND          818..820
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           822..831
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           836..838
FT                   /evidence="ECO:0007829|PDB:6FER"
FT   HELIX           842..849
FT                   /evidence="ECO:0007829|PDB:6FER"
SQ   SEQUENCE   855 AA;  96736 MW;  78662021BC53E1A0 CRC64;
     MILIPRMLLV LFLLLPILSS AKAQVNPAIC RYPLGMSGGQ IPDEDITASS QWSESTAAKY
     GRLDSEEGDG AWCPEIPVEP DDLKEFLQID LHTLHFITLV GTQGRHAGGH GIEFAPMYKI
     NYSRDGTRWI SWRNRHGKQV LDGNSNPYDI FLKDLEPPIV ARFVRFIPVT DHSMNVCMRV
     ELYGCVWLDG LVSYNAPAGQ QFVLPGGSII YLNDSVYDGA VGYSMTEGLG QLTDGVSGLD
     DFTQTHEYHV WPGYDYVGWR NESATNGYIE IMFEFDRIRN FTTMKVHCNN MFAKGVKIFK
     EVQCYFRSEA SEWEPNAISF PLVLDDVNPS ARFVTVPLHH RMASAIKCQY HFADTWMMFS
     EITFQSDAAM YNNSEALPTS PMAPTTYDPM LKVDDSNTRI LIGCLVAIIF ILLAIIVIIL
     WRQFWQKMLE KASRRMLDDE MTVSLSLPSD SSMFNNNRSS SPSEQGSNST YDRIFPLRPD
     YQEPSRLIRK LPEFAPGEEE SGCSGVVKPV QPSGPEGVPH YAEADIVNLQ GVTGGNTYSV
     PAVTMDLLSG KDVAVEEFPR KLLTFKEKLG EGQFGEVHLC EVEGMEKFKD KDFALDVSAN
     QPVLVAVKML RADANKNARN DFLKEIKIMS RLKDPNIIHL LAVCITDDPL CMITEYMENG
     DLNQFLSRHE PPNSSSSDVR TVSYTNLKFM ATQIASGMKY LSSLNFVHRD LATRNCLVGK
     NYTIKIADFG MSRNLYSGDY YRIQGRAVLP IRWMSWESIL LGKFTTASDV WAFGVTLWET
     FTFCQEQPYS QLSDEQVIEN TGEFFRDQGR QTYLPQPAIC PDSVYKLMLS CWRRDTKNRP
     SFQEIHLLLL QQGDE
//
